CC 90001

Drug Profile

CC 90001

Alternative Names: CC90001

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celgene Corporation
  • Class Anti-inflammatories; Antifibrotics
  • Mechanism of Action Mitogen-activated protein kinase 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis
  • Phase I Hepatic fibrosis

Most Recent Events

  • 26 Jul 2017 Phase-II clinical trials in Idiopathic pulmonary fibrosis in Greece, Canada, Canada, USA (PO) (NCT03142191) (EudraCT2016-003473-17)
  • 19 May 2017 Interim efficacy, adverse event and pharmacodynamic data from a preclinical and phase I trial in Idiopathic pulmonary fibrosis presented at the 113th International Conference of the American Thoracic Society (ICATS-2017)
  • 06 Feb 2017 Celgene completes a phase I trial in Idiopathic pulmonary fibrosis in USA and Australia (NCT02510937)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top